OPTN Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of OptiNose, to Paratek Pharmaceuticals

Core Viewpoint - The law firm Wohl & Fruchter LLP is investigating the fairness of the proposed sale of OptiNose, Inc. to Paratek Pharmaceuticals for $9.00 per share in cash, plus a contingent value right worth $5.00 per share, due to concerns that the sale price is below analyst price targets and the company's recent high [1][2][3]. Group 1 - The sale price of $9.00 per share, including the CVR, is below the price targets set by at least three Wall Street analysts, which are $18.00, $17.00, and $15.00 per share [5]. - The proposed sale price is significantly lower than OptiNose's 52-week high of $25.80, indicating that the deal may be opportunistic [2][3]. - The investigation aims to determine if the OptiNose Board of Directors acted in the best interests of shareholders and whether all material information regarding the transaction has been disclosed [4].